Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s):  CLAZF

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.


TSXV:CLAS.H - Post by User

Comment by whisky11on Apr 28, 2021 11:42am
92 Views
Post# 33082573

RE:RE:RE:RE:RE:RE:Reverse split is a necessity

RE:RE:RE:RE:RE:RE:Reverse split is a necessity=Red~One]If NO in the Gaseous form is effective to treat Covid why aren't hospitals administering it ? I know it must be administered properly with the right equipment , so why isn't it being done?

whisky11: usually it is used to treat newborn children with lungs problem. There's not too many machines to administrate NO gas and not enough trained stuff to operate it. After administration in gas form, NO evolves into some dangerous chemical.
Not an issue with R-107 after administration it changes into R-110 end it has ability to protect body of the patient.
R-107 kills the germs and protect your lungs from damage created by the virus and also from exposure to NO.
Look at Sanitize nasal spray, it's approved in Israel and New Zealand, guess what people dying somewhere else, but you can't buy nasal spray in the countries where is urgently needed
Weird or what?

<< Previous
Bullboard Posts
Next >>